thought call
solid result guidanc shift focu life beyond humira oper
strong better-than-expect top bottom line result note
top line guidanc revenu approach consensusdriven
oper strength fx benefit bottom line increas guidanc octob
nearli due impact us tax reform estim tax
rate lowest among peer product perspect humira
growth us slow ou sale expect peak year outlook
hcv sale signal compani believ mavyret take
share market like expens gilead given posit oper
outlook less concern near-term perform still cautiou
pipelin make-up see like success mani late-stag pipelin asset
cautiou compani estim risk adjust revenu
futur humira rel known multipl asset indic
success support number tax better-than-expect near-
term outlook rais pt maintain ew
pipelin focu elagolix rova-t risankizumab pipelin
perspect see multipl import catalyst play notabl
believ elagolix approv endometriosi come also expect data
rova-t sclc addit triniti studi plan studi
rova-t combin opdivo yervoy interest play view
program continu ad rawith full phase ad data aad
februari addit phase program indic risankizumab
could take share ra/ad psoriasi respectivelybut given competit
remain mute long-term forecast
model chang given recent trend commentari updat
model forecast ep
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
larg behind us due settlement
less concer futur franchis
piplin beyond core product
interest like sucess unsur
enough make revenu come
introduct humira biosimilar
pipelin sucess multipl asset indic
would drive revenu thu shrare price upsid
lessen impact humira biosimilar could also
wors expect impact humira biosimialr
entrant competit prior amgevita
failur pipelin asset could also hamper long-term
given recent trend commentari updat model notabl
modifi tax rate reflect compani assumpt us tax reform also
increas revenu assumpt forecast ep
figur detail
increas price target lower tax rate assumpt
higher revenu notabl valu use discount cash flow analysi
assum wacc impli intrins valu per share
million except per share itemspriorcurrentpriorcurrenthumira non-oper incom ep barclay abbvi inc
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
